Friday, October 28, 2011 3:57:30 PM
Don,
Thanks for all that financing hx.
I don't think the co specifically misrepresented his intentions on the 8K.
But, after he took the action(and they were unable to independently verify his motivations), it would only make sense for them to accept and restate his contentions.
In other words, although he may very well have had a private investment to finance, and he may have enlisted the cooperation of an existing institutional investor in the transaction, I'm still inclined to think he knew this was coming.I.E.since borrowing rates are so low these days (if you have decent credit), why would one dump such a large position at such a low price, unless you wanted to avoid something like this.
My other issue is, since they've never resorted to warrant issuance before this, why would they now?
Kind of speaks to a measure of desperation to me.
In any event, I currently have an order in to purchase at 1.00/share now, which could get filled the way things appear to be going.
I'm inclined to think it's because the prospect of warrant overhang is weighing heavily on the stock.
From my experience with Ariad and other stocks it represents a concern for me(both in terms of the greater potential for stock manipulation it affords, as well as why they needed to resort to it at all-again, suggests a measure of desperation).
Thanks again for the feedback.
bw
Thanks for all that financing hx.
I don't think the co specifically misrepresented his intentions on the 8K.
But, after he took the action(and they were unable to independently verify his motivations), it would only make sense for them to accept and restate his contentions.
In other words, although he may very well have had a private investment to finance, and he may have enlisted the cooperation of an existing institutional investor in the transaction, I'm still inclined to think he knew this was coming.I.E.since borrowing rates are so low these days (if you have decent credit), why would one dump such a large position at such a low price, unless you wanted to avoid something like this.
My other issue is, since they've never resorted to warrant issuance before this, why would they now?
Kind of speaks to a measure of desperation to me.
In any event, I currently have an order in to purchase at 1.00/share now, which could get filled the way things appear to be going.
I'm inclined to think it's because the prospect of warrant overhang is weighing heavily on the stock.
From my experience with Ariad and other stocks it represents a concern for me(both in terms of the greater potential for stock manipulation it affords, as well as why they needed to resort to it at all-again, suggests a measure of desperation).
Thanks again for the feedback.
bw
Recent CPRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:23:18 PM
- Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance • GlobeNewswire Inc. • 02/25/2026 09:07:55 PM
- Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference • GlobeNewswire Inc. • 02/24/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 10:04:15 PM
- Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:03:17 PM
- Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies • GlobeNewswire Inc. • 01/08/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:30 PM
- The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) • GlobeNewswire Inc. • 01/05/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:15 PM
- Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/15/2025 01:03:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/12/2025 09:25:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/10/2025 10:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2025 10:00:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/26/2025 06:54:26 PM
